Waystar to Purchase Iodine Software for $1.25B to Strengthen AI-Driven Healthcare Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 20 2025
0mins
Should l Buy WAY?
Source: Yahoo Finance
Acquisition Announcement: Waystar Holding Corp. has agreed to acquire Iodine Software for $1.25 billion, with funding split between cash and stock, resulting in Waystar shareholders owning approximately 92% of the new entity.
Integration and Benefits: The acquisition aims to enhance Waystar’s cloud-based platform by incorporating Iodine's AI-powered clinical intelligence software, which is expected to serve 17 of the top 20 US News Best Hospitals.
Projected Synergies: The companies anticipate over $15 million in cost synergies within two years post-acquisition, leveraging IodineIQ to automate healthcare tasks based on patient encounters and clinical data.
Investment Perspective: While Waystar is viewed as a strong investment opportunity, some analysts suggest that other AI stocks may offer better upside potential and lower risk.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WAY
Wall Street analysts forecast WAY stock price to rise
17 Analyst Rating
16 Buy
1 Hold
0 Sell
Strong Buy
Current: 23.770
Low
40.00
Averages
47.81
High
54.00
Current: 23.770
Low
40.00
Averages
47.81
High
54.00
About WAY
Waystar Holding Corp. provides healthcare organizations with mission-critical cloud software that simplifies healthcare payments. The Company’s enterprise-grade platform, Waystar, streamlines the complex processes. It leverages internally developed artificial intelligence (AI) as well as proprietary, advanced algorithms to automate payment-related workflow tasks and drive continuous improvement, which enhances claim and billing accuracy, enriches data integrity, and reduces labor costs for providers. Its software is used daily by providers of all types and sizes across the continuum of care, including physician practices, clinics, surgical centers, and laboratories, as well as large hospitals and health systems. The Company’s clients utilize its software to manage pre-encounter workflows, such as eligibility checks and prior authorization approvals, as well as mid- and post-encounter workflows, such as co-pay collection, claims submission and monitoring, and payer remittances.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
WAYSTAR HOLDING CORP: MORGAN STANLEY BEGINS COVERAGE WITH EQUAL WEIGHT RATING AND SETS PRICE TARGET AT $28
Company Overview: Waystar Holding Corp is highlighted in a report by Morgan Stanley, indicating its significance in the market.
Coverage Rating: Morgan Stanley initiates coverage of Waystar with an equal weight rating, suggesting a neutral outlook on the stock's performance.
Price Target: The firm sets a price target of $28 for Waystar, providing investors with a benchmark for potential investment decisions.
Market Implications: The initiation of coverage and the established price target may influence investor sentiment and trading activity related to Waystar Holding Corp.
See More
Blue Door Asset Management Increases Waystar Holdings
- Share Purchase Transaction: Blue Door Asset Management disclosed a purchase of 322,600 shares of Waystar on February 17, 2026, valued at approximately $11.49 million, indicating confidence in the company despite a 31.5% decline in its stock price over the past year.
- Quarterly Performance Highlights: Waystar reported $1.10 billion in revenue for 2025, a 17% year-over-year increase, with adjusted EBITDA reaching about $462 million, up 21%, showcasing strong profitability and demand in the healthcare software sector.
- Market Performance Analysis: Despite a significant drop in Waystar's stock price over the past year, the company achieved a 24% revenue growth in the fourth quarter to approximately $304 million, reflecting ongoing demand for automation tools among healthcare providers and the company's competitive position in the industry.
- Investment Outlook: Waystar projects revenue of about $1.28 billion and adjusted EBITDA of $535 million for 2026, and Blue Door's increased stake signals confidence in the healthcare software sector and a preference for a diversified investment portfolio.
See More
Blue Door Increases Stake in Waystar with $11.49 Million Purchase
- Increased Stake: Blue Door Asset Management purchased 322,600 shares of Waystar on February 17, 2026, for an estimated $11.49 million, indicating confidence in the company despite its recent stock performance struggles.
- Position Value Rise: Following the transaction, Blue Door's total stake in Waystar reached 402,300 shares, valued at $13.18 million, reflecting a $10.15 million increase at quarter-end due to both share additions and price appreciation.
- Strong Financial Performance: Waystar reported $1.10 billion in revenue for 2025, a 17% year-over-year increase, with adjusted EBITDA of approximately $462 million, up 21%, showcasing robust profitability in the healthcare technology sector.
- Future Growth Expectations: Waystar projects revenue of about $1.28 billion and adjusted EBITDA of $535 million for 2026, highlighting the company's ongoing growth potential in the healthcare software market, which has prompted Blue Door to double down on its investment.
See More
Blue Door Asset Management Increases Stake in NICE
- Share Increase: Blue Door Asset Management acquired an additional 88,100 shares of NICE in Q4 2025, with an estimated transaction value of $10.64 million, indicating confidence in the company's future growth prospects.
- Value Growth: The value of NICE's position at quarter-end rose by $8.22 million, reflecting both the addition of shares and price appreciation, showcasing the company's robust performance in the market.
- Financial Performance: NICE generated $2.95 billion in revenue for 2025, an 8% year-over-year increase, with its cloud segment growing 13% to $2.24 billion, highlighting strong demand in the digital transformation space.
- Market Performance: Despite a 16.5% decline in NICE's stock price over the past year, shares have risen about 4% at the start of 2026, demonstrating investor recognition of its long-term value.
See More
Waystar Expands Collaboration with Google Cloud for AI-Driven Revenue Cycle
- Enhanced AI Capabilities: Waystar's expanded collaboration with Google Cloud leverages Gemini large language models and cloud infrastructure to further enhance its AI-driven revenue cycle management capabilities, which is expected to accelerate innovation and improve market competitiveness.
- Data Integration Advantage: By capturing and normalizing rich financial and clinical data across a network of over one million healthcare providers, Waystar creates a self-learning revenue cycle that significantly improves efficiency in patient coverage identification and denial prevention.
- Significant Denial Prevention Outcomes: Since launching the industry's first generative AI capabilities for denial prevention and recovery in 2025, Waystar has successfully prevented over $15 billion in denied claims and reduced the time spent on denial appeals and recovery by 90%, greatly enhancing financial performance for healthcare providers.
- Future Outlook: Waystar's autonomous revenue cycle platform aims to minimize provider intervention needs through intelligent agents that continuously learn and operate in real-time, ensuring accuracy and transparency, thereby optimizing the entire healthcare payment ecosystem.
See More
Waystar Expands Collaboration with Google Cloud to Enhance AI Innovations
- Enhanced AI Capabilities: Waystar's expanded collaboration with Google Cloud integrates its agentic AI capabilities directly into revenue cycle workflows, leveraging Gemini large language models and hyperscale infrastructure, which is expected to significantly improve revenue efficiency for healthcare providers.
- Significant Denial Prevention Outcomes: In less than a year, Waystar has successfully prevented over $15 billion in denied claims and reduced the time spent on denial appeals and recovery by 90%, which not only enhances client satisfaction but also strengthens the company's competitive position in the healthcare payment sector.
- Data-Driven Intelligent Decision Making: By integrating financial, clinical, and administrative data from over one million providers, Waystar has built one of the industry's largest proprietary datasets, enabling its AI platform to self-learn and optimize the revenue cycle, ensuring healthcare providers can eliminate friction in financial ecosystems in real-time.
- Future Outlook: Waystar's autonomous revenue cycle platform aims for a future of minimal intervention, allowing healthcare providers to leverage intelligent agents that continuously learn and optimize operations, thereby enhancing accuracy and transparency and further driving digital transformation in the healthcare industry.
See More
WAYSTAR HOLDING CORP: MORGAN STANLEY BEGINS COVERAGE WITH EQUAL WEIGHT RATING AND SETS PRICE TARGET AT $28
Company Overview: Waystar Holding Corp is highlighted in a report by Morgan Stanley, indicating its significance in the market.
Coverage Rating: Morgan Stanley initiates coverage of Waystar with an equal weight rating, suggesting a neutral outlook on the stock's performance.
Price Target: The firm sets a price target of $28 for Waystar, providing investors with a benchmark for potential investment decisions.
Market Implications: The initiation of coverage and the established price target may influence investor sentiment and trading activity related to Waystar Holding Corp.
See More
Blue Door Asset Management Increases Waystar Holdings
- Share Purchase Transaction: Blue Door Asset Management disclosed a purchase of 322,600 shares of Waystar on February 17, 2026, valued at approximately $11.49 million, indicating confidence in the company despite a 31.5% decline in its stock price over the past year.
- Quarterly Performance Highlights: Waystar reported $1.10 billion in revenue for 2025, a 17% year-over-year increase, with adjusted EBITDA reaching about $462 million, up 21%, showcasing strong profitability and demand in the healthcare software sector.
- Market Performance Analysis: Despite a significant drop in Waystar's stock price over the past year, the company achieved a 24% revenue growth in the fourth quarter to approximately $304 million, reflecting ongoing demand for automation tools among healthcare providers and the company's competitive position in the industry.
- Investment Outlook: Waystar projects revenue of about $1.28 billion and adjusted EBITDA of $535 million for 2026, and Blue Door's increased stake signals confidence in the healthcare software sector and a preference for a diversified investment portfolio.
See More
Blue Door Increases Stake in Waystar with $11.49 Million Purchase
- Increased Stake: Blue Door Asset Management purchased 322,600 shares of Waystar on February 17, 2026, for an estimated $11.49 million, indicating confidence in the company despite its recent stock performance struggles.
- Position Value Rise: Following the transaction, Blue Door's total stake in Waystar reached 402,300 shares, valued at $13.18 million, reflecting a $10.15 million increase at quarter-end due to both share additions and price appreciation.
- Strong Financial Performance: Waystar reported $1.10 billion in revenue for 2025, a 17% year-over-year increase, with adjusted EBITDA of approximately $462 million, up 21%, showcasing robust profitability in the healthcare technology sector.
- Future Growth Expectations: Waystar projects revenue of about $1.28 billion and adjusted EBITDA of $535 million for 2026, highlighting the company's ongoing growth potential in the healthcare software market, which has prompted Blue Door to double down on its investment.
See More
Blue Door Asset Management Increases Stake in NICE
- Share Increase: Blue Door Asset Management acquired an additional 88,100 shares of NICE in Q4 2025, with an estimated transaction value of $10.64 million, indicating confidence in the company's future growth prospects.
- Value Growth: The value of NICE's position at quarter-end rose by $8.22 million, reflecting both the addition of shares and price appreciation, showcasing the company's robust performance in the market.
- Financial Performance: NICE generated $2.95 billion in revenue for 2025, an 8% year-over-year increase, with its cloud segment growing 13% to $2.24 billion, highlighting strong demand in the digital transformation space.
- Market Performance: Despite a 16.5% decline in NICE's stock price over the past year, shares have risen about 4% at the start of 2026, demonstrating investor recognition of its long-term value.
See More
Waystar Expands Collaboration with Google Cloud for AI-Driven Revenue Cycle
- Enhanced AI Capabilities: Waystar's expanded collaboration with Google Cloud leverages Gemini large language models and cloud infrastructure to further enhance its AI-driven revenue cycle management capabilities, which is expected to accelerate innovation and improve market competitiveness.
- Data Integration Advantage: By capturing and normalizing rich financial and clinical data across a network of over one million healthcare providers, Waystar creates a self-learning revenue cycle that significantly improves efficiency in patient coverage identification and denial prevention.
- Significant Denial Prevention Outcomes: Since launching the industry's first generative AI capabilities for denial prevention and recovery in 2025, Waystar has successfully prevented over $15 billion in denied claims and reduced the time spent on denial appeals and recovery by 90%, greatly enhancing financial performance for healthcare providers.
- Future Outlook: Waystar's autonomous revenue cycle platform aims to minimize provider intervention needs through intelligent agents that continuously learn and operate in real-time, ensuring accuracy and transparency, thereby optimizing the entire healthcare payment ecosystem.
See More
Waystar Expands Collaboration with Google Cloud to Enhance AI Innovations
- Enhanced AI Capabilities: Waystar's expanded collaboration with Google Cloud integrates its agentic AI capabilities directly into revenue cycle workflows, leveraging Gemini large language models and hyperscale infrastructure, which is expected to significantly improve revenue efficiency for healthcare providers.
- Significant Denial Prevention Outcomes: In less than a year, Waystar has successfully prevented over $15 billion in denied claims and reduced the time spent on denial appeals and recovery by 90%, which not only enhances client satisfaction but also strengthens the company's competitive position in the healthcare payment sector.
- Data-Driven Intelligent Decision Making: By integrating financial, clinical, and administrative data from over one million providers, Waystar has built one of the industry's largest proprietary datasets, enabling its AI platform to self-learn and optimize the revenue cycle, ensuring healthcare providers can eliminate friction in financial ecosystems in real-time.
- Future Outlook: Waystar's autonomous revenue cycle platform aims for a future of minimal intervention, allowing healthcare providers to leverage intelligent agents that continuously learn and optimize operations, thereby enhancing accuracy and transparency and further driving digital transformation in the healthcare industry.
See More
